An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)

NCT01309282 · clinicaltrials.gov ↗
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Hoffmann-La Roche